Publication

Article

Evidence-Based Oncology

Patient-Centered Oncology Care 2015
Volume22
Issue SP3

Panelists Predict FFS Will Grow More Cumbersome

Author(s):

CMS has attempted to tailor ACOs to meet a variety of needs and levels of risk, depending on where parties are in their knowledge level of payment reform.

Tremendous consolidation of re­maining independent oncology practices is very likely under scenarios painted by panelists at the 4th annual meeting of Patient-Centered Oncology Care, pre­sented by The Ameri­can Journal of Managed Care.

The closing panel discussion of the 2-day event brought together an independent prac­tice representative and a former director of medical policy devel­opment for the FDA. CMS has a strong desire to make accountable care organi­zations (ACOs) work, but there are many variables, and panelists said further ex­perimentation with this form of care could have the effect of driving physi­cians out of fee-for-service (FFS) and into Medicare Advantage, where group health programs administer Medicare payment.

However, the degree to which oncol­ogy practices will participate in this migration is unclear because many of them are falling into the gravitational pull of expanding hospital systems, the panelists said. Yale-New Haven Hospi­tal is an example of a growing, all-en­compassing conglomerate, said partici­pant Ted Okon, executive director of the Community Oncology Alliance (COA): “What’s called Jaws in Connecticut is also known as Yale. They’ve bought up everything in the entire state.”

CMS has attempted to tailor ACOs to a variety of health organizations so that each is comfortable with the level of risk it is undertaking though par­ticipation. The Medicare Access & CHIP Reautho­rization Act, for example, offers the choice of par­ticipation in an alterna­tive payment model or FFS. Similarly, the Oncol­ogy Care Model, scheduled for launch in spring of 2016, allows for innovative forms of reimbursement.

To read the remaining article, please visit OncLive.

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo